Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Literature DB >> 301783

Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

D D Von Hoff, J S Penta, L J Helman, M Slavik.

Abstract

A review of 498 patients treated with high-dose methotrexate (MTX) with citrovorum factor rescue revealed 29 drug-related deaths. Until the important factors in those deaths are identified, the use of high-dose MTX should be limited to institutions that possess the necessary supportive facilities and the ability to measure serum levels of the drug.

Entities: Chemical Species

Mesh：

Substances：
Leucovorin
Methotrexate

Year: 1977 PMID： 301783

Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960

Keyword Cloud
Cited

34 in total

1. High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.

Authors: Howard Mutsando; Magid Fahim; Devinder S Gill; Carmel M Hawley; David W Johnson; Maher K Gandhi; Paula V Marlton; Helen G Mar Fan; Peter N Mollee
Journal: Am J Blood Res Date: 2012-01-01

2. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

Authors: D J Grimes; M R Bowles; J A Buttsworth; D B Thomson; P J Ravenscroft; P F Nixon; R F Whiting; S M Pond
Journal: Drug Saf Date: 1990 Nov-Dec Impact factor: 5.606

3. Removal of methotrexate by hemodiafiltration.

Authors: N Montagne; G Milano; C Caldani; J Bracco; P Ayela; E Cassuto; A Thyss; M Schneider
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

4. [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].

Authors: G E Janka; H Wiesner; F Bidlingmaier; R J Haas
Journal: Klin Wochenschr Date: 1979-04-17

5. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors: W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

6. Effective therapy for Burkitt's lymphoma: high-dose cyclophosphamide + high-dose methotrexate with coordinated intrathecal therapy.

Authors: I Ramirez; M P Sullivan; Y Wang; R G Martin; J J Butler
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

1. High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.

2. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

3. Removal of methotrexate by hemodiafiltration.

4. [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].

5. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

6. Effective therapy for Burkitt's lymphoma: high-dose cyclophosphamide + high-dose methotrexate with coordinated intrathecal therapy.

7. Effect of urine pH and flow on renal clearance of methotrexate.

8. Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.

9. Mathematical modeling -- guide to high-dose methotrexate infusion therapy.

10. [Multidrug chemotherapy of osteogenic sarcoma (author's transl)].